Perez-Belmonte, Luis MOsuna-Sanchez, JulioMillan-Gomez, MercedesLopez-Carmona, Maria DGomez-Doblas, Juan JCobos-Palacios, LidiaSanz-Canovas, JaimeBarbancho, Miguel ALara, Jose PJimenez-Navarro, ManuelBernal-Lopez, M RosaGomez-Huelgas, Ricardo2023-01-252023-01-252019-05-21Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, et al. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. Ann Med. 2019 May-Jun;51(3-4):252-261http://hdl.handle.net/10668/13895Introduction: The use of dipeptidyl peptidase-4 inhibitors in hospitalized patients is an area of active research. We aimed to compare the efficacy and the safety of the basal-bolus insulin regimen versus linagliptin-basal insulin in non-critically ill non-cardiac surgery patients in a real-world setting. Methods: We enrolled patients with type 2 diabetes hospitalized in non-cardiac surgery departments with admission glycated haemoglobin level 200 mg/dL (p = .199), and treatment failures (p = .395). Total daily insulin and number of daily insulin injections were lower in the linagliptin-basal group (both p p < .001). Patients on linagliptin-basal insulin had fewer hypoglycaemicevents (blood glucose < 70 mg/dL) (p < .001).Conclusion: For type 2 diabetes surgery patients with mild to moderate hyperglycaemia with-out pre-hospitalization injectable therapies, linagliptin-basal insulin was an effective, safe alterna-tive with fewer hypoglycaemic events in real-world practice.enDiabetes mellitusInpatient hyperglycaemiaLinagliptinNon-cardiac surgeryAgedBlood GlucoseDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDrug Therapy, CombinationFemaleGlycated HemoglobinHospitalizationHumansHypoglycemiaHypoglycemic AgentsInsulinLinagliptinMaleMiddle AgedSafetySpainTreatment FailureTreatment Outcomeresearch article31037970Restricted AccessInsulinaLinagliptinaDiabetes Mellitus Tipo 2Cirugía TorácicaGlucemiaInsuficiencia del Tratamiento10.1080/07853890.2019.16136721365-2060PMC7877876https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877876https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877876/pdf